Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
11.35
+0.05 (0.44%)
At close: Mar 9, 2026, 4:00 PM EDT
11.39
+0.04 (0.35%)
After-hours: Mar 9, 2026, 5:26 PM EDT

Keros Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2018
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2018
Market Capitalization
2246206411,1911,3231,369
Upgrade
Market Cap Growth
-49.91%-3.27%-46.17%-9.94%-3.39%-16.27%
Upgrade
Enterprise Value
-47-561309181,0841,149
Upgrade
Last Close Price
11.3520.3615.8339.7648.0258.51
Upgrade
PE Ratio
4.937.13----
Upgrade
PS Ratio
0.922.54180.637888.64-68.11
Upgrade
PB Ratio
0.732.051.123.594.775.63
Upgrade
P/TBV Ratio
0.742.051.123.594.775.63
Upgrade
P/FCF Ratio
2.115.85----
Upgrade
P/OCF Ratio
2.085.77----
Upgrade
EV/Sales Ratio
--36.576076.87-57.16
Upgrade
Debt / Equity Ratio
0.060.060.030.040.050.00
Upgrade
Debt / EBITDA Ratio
0.210.21----
Upgrade
Debt / FCF Ratio
0.160.16----
Upgrade
Net Debt / Equity Ratio
-0.89-0.89-0.95-0.95-0.96-0.94
Upgrade
Net Debt / EBITDA Ratio
-3.75-3.752.581.872.334.09
Upgrade
Net Debt / FCF Ratio
-2.55-2.553.322.493.733.62
Upgrade
Asset Turnover
0.510.510.010-0.08
Upgrade
Quick Ratio
15.1015.1020.5613.6316.9220.96
Upgrade
Current Ratio
15.4515.4521.4514.2517.2721.23
Upgrade
Return on Equity (ROE)
19.90%19.90%-41.46%-50.19%-40.22%-23.27%
Upgrade
Return on Assets (ROA)
9.25%9.25%-26.73%-31.39%-25.53%-13.43%
Upgrade
Return on Invested Capital (ROIC)
222.22%211.85%-916.80%-1251.82%-887.57%-1027.86%
Upgrade
Return on Capital Employed (ROCE)
22.20%22.20%-35.80%-49.20%-39.60%-23.20%
Upgrade
Earnings Yield
38.88%14.03%-29.22%-12.84%-7.91%-4.29%
Upgrade
FCF Yield
47.34%17.08%-25.39%-10.66%-5.39%-4.61%
Upgrade
Buyback Yield / Dilution
-1.13%-1.13%-27.13%-16.66%-8.17%-50.48%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.